Aduro Biotech to Present at Three Investor Conferences in the Second Half of September
September 18 2017 - 4:02PM
Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Aduro
management will present at three investor conferences in New York,
NY in the second half of September 2017.
- Ladenburg Thalmann 2017 Healthcare Conference on Tuesday,
September 26, 2017 at 8:30 am Eastern Time
- Cantor Fitzgerald Global Healthcare Conference on Wednesday,
September 27, 2017 at 8:35 am Eastern Time
- Leerink Partners Roundtable Series: Rare Disease &
Immuno-Oncology on Thursday, September 28, 2017 at 1:00 pm Eastern
Time
To access the live webcasts and subsequent archived recordings
of these and other company presentations, please visit Aduro's
website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the
discovery, development and commercialization of therapies that
transform the treatment of challenging diseases. Aduro's technology
platforms, which are designed to harness the body's natural immune
system, are being investigated in cancer indications and have the
potential to expand into autoimmune and infectious diseases.
Aduro's LADD technology platform is based on proprietary attenuated
strains of Listeria that have been engineered to express
tumor-associated antigens to induce specific and targeted immune
responses. This platform is being developed as a treatment for
multiple indications, including mesothelioma, gastric, ovarian,
lung and prostate cancers. Additionally, a personalized form of
LADD, or pLADD, is being developed utilizing tumor neoantigens that
are specific to an individual patient’s tumor. Aduro's STING
Pathway Activator platform is designed to activate the STING
receptor in immune cells, resulting in a potent tumor-specific
immune response. ADU-S100 is the first STING Pathway Activator
compound to enter the clinic and is currently being evaluated in a
Phase 1 study in patients with cutaneously accessible metastatic
solid tumors or lymphomas. Aduro’s B-select monoclonal antibody
platform is comprised of a number of immune modulating assets in
research and preclinical development, including BION-1301, an
anti-APRIL antibody. Aduro is collaborating with leading global
pharmaceutical companies to expand its products and technology
platforms. For more information, please visit www.aduro.com.
Contact:
Sylvia Wheeler
SVP, Corporate Affairs
510 809
9264
Media Contact:Susan
Lehner510 809
2137press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Sep 2023 to Sep 2024